Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Predicts Low Birth Weight

By LabMedica International staff writers
Posted on 04 Sep 2012
A protein found in the blood of pregnant women can predict if they are likely to have a fetus that does not grow properly. More...


The assay could lead to a widely available blood test that could help develop ways for improving the outcomes of women and their children who face this high risk of stillbirth and long-term health complications.

Scientists at the Ottawa Hospital Research Institute (ON, Canada) conducted a nested case-control study to examine circulating levels of Insulin Growth Factor Binding Protein 4 (IGBP-4) and other biomarkers by Western blot in early gestation in 36 women who went on to develop fetal growth restriction (FGR) and 36 controls having normal-weight babies.

The investigators found that IGFBP-4 was elevated in early pregnancy compared with nonpregnant women and women in later pregnancy, consistent with the presence of abundant extravillous trophoblasts and decidual cells that highly expressed IGFBP-4. High expression of pregnancy-associated plasma protein-A (PAPP-A) was observed in extravillous trophoblasts and decidual cells in early pregnancy but hardly detectable in the circulation at the same time. The women with high levels of IGFBP-4 were 22 times more likely to give birth to tiny babies, defined as the smallest 5% by weight for their gestational age, than women with normal levels of IGFBP-4.

Andrée Gruslin, MD, the lead author of the study, said, "Usually, we don’t find out until later in a pregnancy that a fetus isn’t growing properly, but this test can tell us in the first trimester if there’s likely to be a problem. By identifying these high-risk pregnancies early on, we will be able to monitor these women more closely and hopefully help them deliver a healthier baby.” Dr. Gruslin hopes that her studies on IGFBP-4 could lead to new approaches that would improve fetal growth in high-risk pregnancies. This condition, called Fetal Growth Restriction or Intrauterine Growth Restriction, is thought to affect 3%-5% of all pregnancies, and cause close to half of all stillbirths. The study was published on August 1, 2012, in the Journal of Clinical Endocrinology and Metabolism.

Related Links:
Ottawa Hospital Research Institute



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.